Skip to main content
. 2022 Jan 24;185(5):847–859.e11. doi: 10.1016/j.cell.2022.01.015

Figure S1.

Figure S1

Assessment of SARS-CoV-2-specific T and B cells by flow cytometry-based assays, related to Figures 1, 2, 3, 5, and 6

(A) Gating strategy for T cell AIM, ICS, and AIM+ICS assays included in this study. These gates and antibodies are the same for all time points. Spike-specific responses are measured for both CD4+ and CD8+ T cells within the same donors using the indicated AIM markers or cytokines.

(B and C) Validation of a combined AIM/ICS assay. The addition of a cocktail of brefeldin and Monesin in the ICS assay significantly decreases the detection of AIM markers, while the inclusion of the CD137 antibody in culture concomitantly, repristinates the response (B) and does not impact the IFNγ detection (C). Data are shown after background subtraction and stimulation index >2. Statistical analyses are performed using a paired Wilcoxon test.

(D–G) Representative gating strategy for the memory B cell assays using spike protein at time point 3 (D) or 4 (E), or RBD at time point 3 (F) or 4 (G).